Abiopharma

🔍 Stovall Bryan Lee (Executive)

Company: AZZ INC (AZZ)

Report Date: 2026-04-24

Detailed Transactions and Holdings:

• Acquired 949 shares of COMMON STOCK (Direct)
  Date: 2026-04-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,658.00 | transaction_form_type: 4
• Acquired 6 shares of COMMON STOCK (Direct)
  Date: 2026-04-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,664.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 324 shares of COMMON STOCK at $143.33 per share (Direct)
  Date: 2026-04-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 23,340.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 949 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,898.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5

Footnotes:

• F1: Reflects the vesting of dividend equivalent rights that accrued on 949 restricted stock units (RSUs) granted on 4/24/2025_, which AZZ has settled in shares of AZZ common stock.
• F2: The reporting person disposed of shares of common stock to satisfy tax withholding obligations.
• F3: Each RSU represents a contingent right to receive one share of AZZ common stock.
• F4: The RSUs were granted on 4/24/2025 under the Companys 2023 Long-Term Incentive Plan and vest ratably over a 3-year period beginning on 4/24/2026.
• F5: Once vested, the shares of common stock are not subject to expiration.